Skip to content

Efficacy of inhaled rhDNase for acute asthma in childhood.

Efficacy of inhaled rhDNase for acute asthma in childhood.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29109
Enrollment
100
Registered
2005-09-06
Start date
2005-09-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute childhood asthma

Interventions

One dose of 5 mg DNase OR one dose of 5 mg placebo in addition to standard care.

Sponsors

Erasmus MC, Sophia Children's Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children, aged 2-18 years, with acute asthma who require at least two doses of bronchodilators at the emergency department.

Exclusion criteria

Exclusion criteria: 1. Dyspnoea due to other causes than asthma; 2. Patients with a concurrent chronic pulmonary disease, such as CF, BPD; 3. Patients with a symptomatic cardial or neuromuscular disease.

Design outcomes

Primary

MeasureTime frame
Improvement in asthma score 1 hour after intervention.

Secondary

MeasureTime frame
1. Need for hospital admission; 2. Duration of hosptial admission; 3. Asthma score at 2,6,12 and 24 hours after intervention; 4. Heart rate, respiratory rate and oxygen saturation; 5. Need for additional oxygen; 6. Number of bronchodilators; 7. Doctor’s visit or readmission and use of rescue bronchodilator aerosol therapy following 72 hours after discharge from EMD; 8. Cost-consequence analysis.

Contacts

Public ContactR. Boogaard

Erasmus Medical Center, Sophia Children’s Hospital, Department of Pediatric Pulmonology, SB-2666, P.O. Box 2060

r.boogaard@erasmusmc.nl+31 (0)10 4636683

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)